Haw Par Corporation Limited

Equities

H02

SG1D25001158

Pharmaceuticals

Delayed Singapore S.E. 10:36:39 2024-05-02 pm EDT 5-day change 1st Jan Change
9.65 SGD -2.03% Intraday chart for Haw Par Corporation Limited -2.23% -1.03%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Haw Par Corporation Limited Announces Board Appointments CI
Haw Par Corporation Limited Proposes One-Tier Tax-Exempt Second and Final Dividend for the Financial Year Ended 31 December 2023, Payable on 21 May 2024 CI
Haw Par Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Haw Par Corporation Limited Announces Retirement of Gn Hiang Meng as Non-Executive and Independent Director CI
Haw Par Corporation Limited Appoints Lee Huey Jee Jenny as Non-Executive and Independent Director CI
Haw Par Corporation Limited Announces Appointment of Wee Ee Chao as Chairman CI
Haw Par Chairman Dies MT
Haw Par Corporation Limited Announces Demise of Wee Cho Yaw as Chairman, Non-Executive and Non-Independent Director CI
Haw Par Corporation Limited(SGX:H02) added to S&P Global BMI Index CI
Haw Par's Net Profit Jumps 35% in H1 MT
Haw Par Corporation Limited Declares First and Interim One-Tier Tax Exempt Dividend for the Financial Year Ending 31 December 2023, Payable on 7 September 2023 CI
Haw Par Corporation Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Haw Par Corporation Limited Approves Second and Final Tax-Exempt Dividend for the Financial Year Ended December 31, 2022 CI
Haw Par Corporation Limited Announces Changes in Composition of Board Committees CI
Haw Par Posts Higher H2 Profit, Revenue MT
Haw Par Corporation Limited Proposes One-Tier Tax-Exempt Second and Final Dividend for the Financial Year Ended 31 December 2022, Payable on 24 May 2023 CI
Haw Par Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Haw Par Corporation Limited(SGX:H02) dropped from S&P Global BMI Index CI
Haw Par Corporation Limited Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Haw Par Corporation Limited Announces First Interim Cash Dividend, Payable on 2 September 2022 CI
Haw Par Corporation Limited Announces Appointment of Chiew Kun Long, Alvin as Company Secretary CI
Haw Par Corporation Limited Approves to Declare One-Tier Tax-Exempt Second & Final Dividend for Fiscal Year 2021 CI
Haw Par Corporation Limited Announces Resignation of Lee Kay Swee as Company Secretary CI
Haw Par's Net Profit Nearly Doubles in H2 2021 as Revenue Zooms 150% MT
Haw Par Corporation Limited Appoints Chow Say Suan to Member of Investment Committee CI
Chart Haw Par Corporation Limited
More charts
Haw Par Corporation Limited is a Singapore-based holding company. The principal activities of the Company are licensing of the Tiger trademarks and owning and holding investments for the long-term. Its segments include Healthcare products, Investments and Others. The Company's Healthcare products segment is engaged in manufacturing and distributing topical analgesic products under the Tiger Balm and Kwan Loong brand. Its Investments segment is engaged in long term investing activities, mainly in quoted securities in Asia. The Company's Others segment includes property division, which owns and leases out several investment properties in Asia, and leisure division, which provides family and tourist-oriented leisure activities in the form of oceanariums. Its Tiger Balm brand products include Tiger Balm White Ointment, Tiger Balm Muscle Rub, Tiger Balm Back Pain Patch and Tiger Balm Muscle Rub. Its Kwan Loong brand products include Kwan Loong Medicated and Oil Kwan Loong Refresher.
Calendar
More about the company